RSV Roundtable: Nirsevimab's Impact
In the third installment of RSV Roundtable, our panel discusses the impact nirsevimab has had this RSV season.
Welcome to the third episode of our 5-episode series; respiratory syncytial virus (RSV) Roundtable, a collaborative project from Contemporary Pediatrics, Contagion, and Contemporary OB/GYN.
This series discusses several aspects of RSV including incidence rates, vaccines, and immunizations.
In this episode, our panel highlights what type of impact nirsevimab (Beyfortus; Sanofi, AstraZeneca) has made this RSV season. In this discussion, the monoclonal antibody's availability and rollout process is also in the spotlight amid a plan to roll out some 230,000 additional doses in January 2024.
Our panel of clinicians includes:
- Robert H. Hopkins Jr., MD: medical director, National Foundation for Infectious Diseases; professor of Internal Medicine and Pediatrics; chief, Division of General Internal Medicine, University of Arkansas for Medical Sciences
- William Muller, MD, PhD: attending physician, Infectious Diseases; Ted Emerson Miller research scholar; professor of Pediatrics (Infectious Diseases), Northwestern University Feinberg School of Medicine; scientific director, Clinical and Community Trials, Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children’s Hospital
- Sallie Permar, MD, PhD: Nancy C. Paduano professor and chair, Department of Pediatrics, Weill Cornell Medicine; pediatrician-in-chief, New York-Presbyterian/Weill Cornell Medical Center
- Laura Riley, MD: chair, Department of Obstetrics and Gynecology, Weill Cornell Medicine; obstetrician and gynecologist-in-chief, New York-Presbyterian/Weill Cornell Medical Center
- Neil Silverman, MD: professor, obstetrics and gynecology, David Geffen School of Medicine, UCLA; director, Maternal-Fetal Medicine Fellowship Program
To view the other episodes, go to our RSV special series page, and watch the first 2.
